{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:07:13Z","timestamp":1770152833080,"version":"3.49.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Colorectal cancer is the second most prevalent cancer in Chile, affecting both sexes. Late-stage diagnosis occurs in approximately 25% of cases, with a five-year survival rate of only 14%. Standard treatment involves surgical resection followed by 5-fluorouracil-based chemotherapy, often combined with oxaliplatin or irinotecan. However, patient responses vary significantly due to genetic polymorphisms affecting drug metabolism, including variants in TYMS, DPYD, GSTs, and DNA repair enzymes. While genetic factors influencing chemotherapy outcomes have been studied, their impact remains unclear and varies across populations. No predictive model integrating genetic and clinical variables for chemotherapy safety in Chilean colorectal cancer patients has been established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to identify relevant genetic variants in <jats:italic>TYMS<\/jats:italic>, <jats:italic>TYMP<\/jats:italic>, <jats:italic>DPYD<\/jats:italic>, <jats:italic>GSTP1<\/jats:italic>, <jats:italic>MTHFR<\/jats:italic>, <jats:italic>ERCC2<\/jats:italic>, <jats:italic>ABCB1<\/jats:italic>, <jats:italic>ABCC2<\/jats:italic>, <jats:italic>ABCC4<\/jats:italic>, and <jats:italic>ABCG2<\/jats:italic> genes, which, combined with clinical factors, could contribute to a predictive model for 5-FU-based chemotherapy safety in advanced colorectal cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective nested case-control study was conducted on 82 advanced colorectal cancer patients. Sixteen genetic variants were analyzed to assess their association with adverse reactions and their severity using logistic regression. Multivariate models were developed to predict chemotherapy safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 16 variants analyzed in 82 patients, key findings included: The G allele of <jats:italic>GSTP1<\/jats:italic> (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036). The C allele of <jats:italic>DPYD<\/jats:italic> (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05). The <jats:italic>TYMS<\/jats:italic> deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001). On the other hand, the 3R genotype of <jats:italic>TYMS<\/jats:italic> 5\u2019UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029). Two multivariate models were developed to predict anemia (p = 0.027) and pain (p = 0.01) development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides a foundation for developing pharmacogenetic-based predictive models for adverse reactions associated with 5-FU, including neuropathy, mucositis, and hematological and skin toxicities. Future research may refine these models to enable personalized dose adjustments, improving chemotherapy safety in Chilean colorectal patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1589724","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:29Z","timestamp":1753416629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Leslie C.","family":"Cerpa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Cay\u00fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Lavanderos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Alarc\u00f3n-Concha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Kaempfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Moreno-Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo S.","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Gutierrez-C\u00e1ceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Barajas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Donoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson M.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"B3","unstructured":"Gu\u00eda Cl\u00ednica AUGE C\u00e1ncer Colorrectal\n          \n          \n          \n          2013"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-9-154","article-title":"Treatment of colorectal liver metastases","volume":"9","author":"Ismaili","year":"2011","journal-title":"World J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2011.02765.x","article-title":"A systematic review of treatment guidelines for metastatic colorectal cancer","volume":"14","author":"Edwards","year":"2012","journal-title":"Color Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.ANNONC.2022.10.003\/ATTACHMENT\/0CA0C13F-F566-49FF-A0D0-E3D28EF76DB6\/MMC1.PDF","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16142597\/S1","article-title":"Chemotoxicity and Associated risk factors in colorectal cancer: A systematic review\u00a0and meta-analysis","volume":"16","author":"Han","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: precision medicine and drug response","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0102-4","article-title":"Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer","volume":"20","author":"L\u00f3pez-Cort\u00e9s","year":"2020","journal-title":"Pharmacogenom J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872017000400009","article-title":"Clinical applications of pharmacogenomics","volume":"145","author":"Qui\u00f1ones","year":"2017","journal-title":"Rev Med Chil"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8030163","article-title":"Clinical application and educational training for pharmacogenomics","volume":"8","author":"Guy","year":"2020","journal-title":"Pharmacy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/CLPT.2013.172","article-title":"Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.29654","article-title":"Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines","volume":"137","author":"Toffoli","year":"2015","journal-title":"Int J cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.8.1079","article-title":"Pharmacogenetics in colorectal cancer: a systematic review","volume":"9","author":"Funke","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.64","article-title":"MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II\/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin","volume":"15","author":"Cecchin","year":"2015","journal-title":"Pharmacogenom J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1467","article-title":"Polymorphisms of GSTP1, ERCC2 and TS-3\u2032UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients","volume":"6","author":"Kumamoto","year":"2013","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601975","article-title":"A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer","volume":"91","author":"Stoehlmacher","year":"2004","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north american gastrointestinal intergroup trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12032-013-0802-6\/TABLES\/5","article-title":"Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer","volume":"31","author":"Zhao","year":"2014","journal-title":"Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-07491-3","article-title":"A polymorphism in ABCC4 is related to efficacy of 5-FU\/capecitabine-based chemotherapy in colorectal cancer patients","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2019.00206","article-title":"Association study among candidate genetic polymorphisms and chemotherapy-related severe toxicity in testicular cancer patients","volume":"10","author":"Lavanderos","year":"2019","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S261208","article-title":"IL-6 -572C>G and CARD8 304T>A genetic polymorphisms are associated with the absolute neutrophil count in patients with hematological Malignancies under chemotherapy: an application of multilevel models to a preliminary pharmacogenetic study","volume":"13","author":"Martinez","year":"2020","journal-title":"Pharmgenom Pers Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/NMETH0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"W452","DOI":"10.1093\/NAR\/GKS539","article-title":"SIFT web server: predicting effects of amino acid substitutions on proteins","volume":"40","author":"Sim","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B27","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0\n          \n          \n          \n          2017"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1200\/JCO.22.02364","article-title":"DPYD testing: time to put patient safety first","volume":"41","author":"Baker","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1186\/s12885-021-08745-0","article-title":"A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer","volume":"21","author":"Cordova-Delgado","year":"2021","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1071","article-title":"Ensembl 2025","volume":"53","author":"Dyer","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.009","article-title":"Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy","volume":"102","author":"Madi","year":"2018","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-022-04491-7","article-title":"Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype","volume":"91","author":"Medwid","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211024464","article-title":"Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes","volume":"14","author":"Saif","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010077","article-title":"TYMS 3\u2019-UTR polymorphism: A novel association with FOLFIRINOX-induced neurotoxicity in pancreatic cancer patients","volume":"14","author":"Emelyanova","year":"2021","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104594","article-title":"Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis","volume":"152","author":"Hamzic","year":"2020","journal-title":"Pharmacol Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12885-020-06924-z","article-title":"Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival","volume":"20","author":"Salimzadeh","year":"2020","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13166","article-title":"Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India","volume":"45","author":"Varma","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Shirota","year":"2001","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e78053","DOI":"10.1371\/journal.pone.0078053","article-title":"Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [published correction appears in PLoS One. 2015 Apr 13;10(4):e0124893. doi: 10.1371\/journal.pone.0124893","volume":"8","author":"Jennings","year":"2013","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.262","article-title":"Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity","volume":"108","author":"Loganayagam","year":"2013","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916650","article-title":"Effects of polymorphisms in the MTHFRgene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients","volume":"12","author":"Atasilp","year":"2022","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2020.09.016","article-title":"Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma","volume":"35","author":"Puerta-Garc\u00eda","year":"2020","journal-title":"Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3478-3","article-title":"DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer","volume":"81","author":"Nahid","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.15.1000","article-title":"Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins","volume":"272","author":"Ali-Osman","year":"1997","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-137","article-title":"Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum\/5-Fu-based chemotherapy: a systematic review","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12957-020-02103-3","article-title":"Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms","volume":"18","author":"Deng","year":"2020","journal-title":"World J Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2020.0285","article-title":"DPYDc.1905\u2009+\u20091G>A promotes fluoropyrimidine-induced anemia, a prognostic factor in disease-free survival, in colorectal cancer","volume":"25","author":"Deligonul","year":"2021","journal-title":"Genet Test Mol Biomarkers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589724\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:10:30Z","timestamp":1753416630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589724\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":47,"alternative-id":["10.3389\/fonc.2025.1589724"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1589724","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1589724"}}